GINA MANGIN: Open Payments
NPI 1861450553 · ORLANDO, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$62,855 in 167 payments from 19 companies in 2025. Trend: 2023 $71,492 · 2024 $69,680 · 2025 $62,855
Speaker / faculty: $28,440Consulting: $19,732Travel & lodging: $10,056Food & beverage: $4,443Education: $184
| Company | Payments | Amount |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 38 | $14,710 |
| GENZYME CORPORATION | 18 | $12,366 |
| Incyte Corporation | 26 | $11,647 |
| ABBVIE INC. | 25 | $11,168 |
| Novartis Pharmaceuticals Corporation | 11 | $6,520 |
| Eli Lilly and Company | 3 | $3,182 |
| UCB, Inc. | 3 | $1,223 |
| Janssen Biotech, Inc. | 7 | $480 |
| Galderma Laboratories, L.P. | 7 | $377 |
| LEO Pharma Inc. | 8 | $367 |
Products named: DUPIXENT, SKYRIZI, OPZELURA, EBGLYSS, RINVOQ, Bimzelx, TREMFYA, NEMLUVIO.
Industry payments across FL — which companies pay providers there.
